ArticleFrontiers in cardiovascular medicine2026
Neutrophil percentage-to-albumin ratio is an independent risk factor for MACEs in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between neutrophil percentage-to-albumin ratio and bone mineral density and prevalent osteoporosis in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Association between neutrophil percentage-to-albumin ratio and adverse clinical outcomes after successful percutaneous coronary intervention for chronic total occlusion: a cohort study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Neutrophils are well-established biomarkers of systemic inflammation, whereas serum albumin levels are commonly used as reliable indicators of nutritional status. The neutrophil percentage-to-albumin ratio (NPAR), a novel composite biomarker integrating inflammatory and nutritional parameters, has shown promising predictive value across a range of clinical settings. However, its association with outcomes in patients with acute coronary syndrome (ACS) remains unclear. This study aimed to evaluate the prognostic utility of NPAR for predicting major adverse cardiovascular events (MACEs) in patients with ACS. Patients and methods: From January 2016 to December 2018, 1553 consecutive patients with ACS undergoing percutaneous coronary intervention (PCI) were enrolled at the Affiliated Hospital of Chengde Medical University. The NPAR was calculated as the admission neutrophil percentage divided by serum albumin concentration. Serum albumin was measured in g/L and converted to g/dL (dividing by 10) for NPAR calculation to align with conventional units. The primary follow-up endpoints were MACEs, comprising all-cause mortality and heart failure readmission. Results: During follow-up, 1,524 patients completed the study; 55 of them experienced MACEs. The NPAR levels differed significantly between the MACE and non-MACE groups ( Conclusion: NPAR ≥ 17.326 is an independent prognostic risk factor for patients with ACS undergoing PCI and may be a valuable clinical marker for identifying high-risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.